Left to right: Dr Oskar Wenbar, and Dr Thuria Wenbar, co-founders of Evaro (Credit: Evaro)
Digital healthcare platform Evaro announced that it has closed a $25 million (£18m) Series A funding round to accelerate its healthcare-as-a-service model.
Founded in 2018 by emergency physician Dr Thuria Wenbar and pharmacist researcher Dr Oskar Wenbar, Evaro serves three markets: consumer brands wanting to generate new revenue; healthcare providers expanding digital capacity for common conditions; and employers deploying health benefits.
The NHS-licensed platform partners with period-tracking app Clue and sexual wellness retailer Lovehoney, embedding prescription services into their customer experiences.
Evaro says that the funding will be used to boost its healthcare-as-a-service model; allow expansion across women’s health, men’s health, and longevity medicine; and grow its clinical capabilities and platform development.
Thuria Wenbar, chief executive and co-founder of Evaro, said: “When a third of people are waiting over a week just to see their GP, it’s time to think through alternative solutions that help people get the care they need while supporting NHS capacity.
“What we’ve built is infrastructure that allows our partners – brands people already trust – to deliver safe and regulated healthcare for common conditions without having to build a thing.
“We’re making healthcare as accessible as online banking, and this funding lets us prove that model works at scale.”
Evaro aims to help alleviate the burden on the NHS by providing complete regulated healthcare infrastructure that can be embedded into any platform people spend time on, such as asynchronous consultations, remote diagnostics, prescribing, dispensing, and aftercare.
For partners, the model creates a new revenue stream while deepening customer relationships through an expanded health offering.
In October 2025, Evaro partnered with FemTech startup Clue to provide access to NHS-funded contraception through the firm’s period-tracking app. Through the integration Clue’s UK user base can order contraception through Evaro’s embedded pharmacy infrastructure,
Oskar Wenbar, chief medical officer and co-founder, said: “Patients now expect the same convenience from healthcare that they get from banking or shopping—instant, mobile, on their terms.
“The technology exists to deliver this for minor conditions, but our system is still stuck requiring appointments, phone calls, physical visits – with no capacity for smart aftercare. We want to solve this, and scale the infrastructure that matches how people actually want to access care in 2026.”
The funding round was led by AlbionVC, with participation from Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC, and BBI.
Christoph Ruedig, partner at AlbionVC, who joins Evaro’s board, said: “We’ve seen embedded finance transform banking, Evaro is now driving the embedded health revolution.
“Evaro has spent seven years building its infrastructure properly, with deep regulatory credentials.
“This now allows consumer brands to enter the healthcare space safely, unlocking massive latent demand while relieving pressure on the NHS. We are thrilled to back the team as they define this new category.”
The post Digital healthcare platform Evaro raises £18m to fund expansion first appeared on TechToday.
This post originally appeared on TechToday.